What Is Lunai Bioworks Inc. (LNAI) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Lunai Bioworks Inc.'s intrinsic value is estimated at a composite fair value of $3.52. While the stock appears modestly undervalued at $2.98 (implied upside of +18.3%), our analysis suggests a thinner margin of safety across 3 of 5 bullish models. Notably, CUCE sees the most upside at +149.3% (fair value: $7.43), while First Chicago is the most conservative at -88.5% ($0.34). The spread between these extremes — +237.8% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About LNAI?
5 of 13 models are currently active for LNAI. Of these, 3 models suggest upside while 2 models suggest overvaluation. The Bayesian DCF estimates LNAI's intrinsic value at $1.59, implying -46.8% downside from the current price. See which stocks rank higher →
How Does LNAI Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, LNAI ranks #387 by Quality of Company score. CirclFi's QOC score of 3.1/10 evaluates 32 fundamental signals. A score of 3.1 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to healthcare company businesses. For Lunai Bioworks Inc., metrics like R&D productivity ratio provide important context that general-purpose valuation models may underweight.
Is LNAI a Value Trap?
CirclFi's Value Trap algorithm assigns LNAI a score of 37/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
5 of 13 models are active for Lunai Bioworks Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Lunai Bioworks Inc. scores 3.1 out of 10 on our 32-signal quality assessment, a weak rating that exhibits fundamental weaknesses that warrant careful scrutiny. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +237.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every LNAI valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across LNAI's 5 active models, average confidence is 18%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad